Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by synovial hyperplasia and progressive destruction of cartilage and bone. 1 The cytokine profile of the joint in active disease is dominated by macrophage and fibroblast products, 2 although small quantities of T cell lymphokines have been identified. Of T cell products produced by the rheumatoid joint, the majority are derived from cells exhibiting the T helper 1 (Th1) phenotype, including gamma interferon (IFN-␥). T helper subset 2 (Th2)-derived cytokines, including IL-4 and IL-13, suppress Th1 function as well as pro-inflammatory cytokine production. The rheumatoid joint is essentially devoid of Th2 lymphokines, and Th1/Th2 imbalance has been suggested as a mechanism for disease perpetuation in RA. 3 In animal models of arthritis, increased endogenous Th2 cytokine production correlates with disease resolution 4, 5 and administration of exogenous IL-4 or IL-13 ameliorates disease. [6] [7] [8] Due to evidence implicating low Th2 cytokine production in RA, we evaluated intra-articular gene therapy with a Th2 cytokine as a way to suppress synovial inflammation in an animal model of arthritis. Although adenoviral vectors have been successfully tested in such models, [9] [10] [11] [12] [13] their short duration of expression and the host's pro-inflammatory response to viral proteins have limited the usefulness of this vector in humans. To avoid these problems, we produced a retroviral vector encoding the rat IL-4 gene and determined its therapeutic effect in adjuvant arthritis after direct intra-articular gene transfer. Because of the relatively low transfection efficiency of retroviruses in vivo, previous studies using retroviral gene therapy in arthritis have focused on ex vivo gene transfer. Examples of this approach have included in vitro infection of cultured fibroblasts or lymphocytes with retroviruses encoding cytokine inhibitors (IL-1ra, soluble TNF receptors) or interferon (IFN-␤) before reinjection into the host. [14] [15] [16] [17] After the engineered cells are administered to the animal, they produce the transgene product wherever they localize. While beneficial effects have been observed, this approach has limited applicability in treating large numbers of patients.
Our focus on direct intra-articular administration as an efficient means of gene transfer with limited systemic exposure led us to optimize methods for retroviral gene therapy in arthritis. These studies demonstrated that successful synovial transduction could be achieved by direct intra-articular gene transfer using retroviral constructs and that long-term local gene expression occurred without inducing inflammation. 18 Although the levels of expression after retroviral gene therapy are relatively low compared with adenoviral vectors, this approach is potentially ideal for cytokines where very low concentrations can have profound biologic sequelae. The present study is the first to demonstrate that direct intra-articular transduction using a retrovirus can have therapeutic benefits in arthritis. Specifically, we showed that intraarticular transduction with the IL-4 gene is clinically effective in rat adjuvant arthritis. Of particular interest, increased IL-4 protein was also noted in contralateral joints, suggesting that locally increased concentrations of Th2 cytokines in the joint can enhance Th2 functions generally.
Results

IL-4 gene transfer in cultured fibroblast-like synoviocytes (FLS)
Cultured human FLS were infected with the DA-IL-4 retroviral construct in vitro to determine retroviral transgene expression and stability. We have previously shown that human FLS behave similarly to rat FLS with regard to retroviral gene transfer. 18 Cultured FLS were incubated with increasing concentrations of DA-IL-4 for 3 h, washed, and re-cultured with fresh media. The supernatants were sampled 8 h, 3 days, 6 days and 9 days later and assayed for immunoreactive IL-4. Figure 1 shows a concentration and time-dependent increases in IL-4 production by transduced FLS. Continued accumulation of IL-4 in the supernatants over the entire time-period indicated that the transgene was stable in vitro for at least 9 days, indicating that the transduced FLS can produce IL-4 and that production of this cytokine is not toxic to the cells. Effect of IL-4 gene therapy on IL-4 production After demonstrating successful transduction of cultured FLS with DA-IL-4, we determined whether the construct could increase IL-4 production in inflamed joints. To establish a baseline, the time-course of IL-4 expression in rats with adjuvant arthritis was evaluated after treatment with a control retrovirus. On day 12, DA-␤-gal was injected into the right ankle of arthritic rats. Figure 2 shows that only a small amount of IL-4 was present in the joints of normal animals without vector injection and without adjuvant arthritis. Significantly greater IL-4 production was observed on day 15 and the amount increased further on day 20 as the disease reached a plateau. Similar levels were obtained in arthritic animals that had not received any intra-articular injections, indicating that retroviral administration alone had no effect on endogenous IL-4 production (data not shown). These studies show that IL-4 production increases during both the initiation and chronic stages of adjuvant arthritis. High production of IL-4 on day 20 correlated with the plateau phase of disease.
We then determined if treatment with DA-IL-4 increased articular IL-4 production. Animals were immunized on day 0 and injected with DA-IL-4 on day 12 as described in Materials and methods. Three days later (day 15 after immunization), IL-4 protein was measured in the injected and contralateral joints. To calculate the net effect of transgene expression above endogenous IL-4 production, the data were normalized by subtracting IL-4 concentrations in animals that had been injected with DA-␤-gal (see Figure 2) . Figure 3 shows that IL-4 production was modestly higher in the DA-IL-4-treated joint. Although the increase was only 10-15% over the amount detected in the contralateral joints on day 15, the findings were consistent and were statistically significant (P Ͻ 0.001; n = 7).
Figure 3 IL-4 expression in joints after DA-IL-4 injection. Lewis rats were immunized at the base of the tail with complete Freund's adjuvant and DA-IL-4 was injected into the right ankle on day 12 after immunization as described in Materials and methods. On day 15 or 20, the injected (right) and contra-lateral (left) ankles were harvested and assayed for immunoreactive IL-4. IL-4 levels of DA-␤-gal-treated animals (see
By day 20, IL-4 expression was substantially higher in the injected joints compared with that of the DA-␤-galtreated joints, indicating that IL-4 accumulation continued for at least 1 week (P Ͻ 0.001 for day 20 compared with day 15; n = 15). More intriguing, IL-4 production in the contralateral joint also increased by day 20 and reached the same level as in the injected joint. This is even more striking when one considers that only a small percentage of transduced cells from the retrovirusinjected ankle migrate to other sites of the body (either joints or internal organs) in this model. IL-4 levels were also increased by day 20 in the serum of animals that had been treated with intra-articular DA-IL-4 (760 ± 168 pg/ml in DA-␤-gal-treated rats and 2810 ± 180 pg/ml in DA-IL-4-treated rats; P Ͻ 0.05). IL-4 levels in normal rats was 272 ± 17 pg/ml. To determine the source of the IL-4 at distant sites, RT-PCR was performed on mRNA isolated from both the injected and contralateral joints of rats injected with DA-IL-4. As shown in Figure 4 , IL-4 gene expression was readily demonstrated in the injected ankle. However, IL-4 mRNA was below the level of detection in the contralateral paw even though the IL-4 protein was increased. This suggests that the injected joint is the source of IL-4 in the distant sites.
To determine if DA-IL-4 also altered expression of another cytokine, the joint samples were also assayed for the Th1 cytokine IFN-␥. Unlike IL-4, IFN-␥ concentrations were below the level of detection throughout adjuvant 
RT-PCR was performed on pooled ankle mRNA as described in Material and methods (n = 3 per group). Note that IL-4 mRNA was detected in the DA-IL-4-injected ankles but was below the level of detection in contralateral joints or DA-␤-galinjected joints. G3PDH was expressed in all samples.
arthritis and remained undetectable in injected and contralateral paws after DA-IL-4 treatment.
Clinical effect of intra-articular IL-4 gene therapy
Clinical studies were then performed to evaluate the effect of DA-IL-4 and DA-␤-gal on joint swelling in adjuvant arthritis. When animals were treated with DA-IL-4 on day 12, paw swelling was significantly decreased in the injected paw compared with a separate group of animals that had been treated with the control DA-␤-gal vector (P Ͻ 0.05) (see Figure 5a ). Figure 5b shows that swelling in the DA-IL-4-injected paws was also significantly less than the contralateral uninjected paws of the same animals. Finally, DA-␤-gal treatment alone had no effect on paw swelling (see Figure 5c ). Hence, a therapeutic effect on paw swelling was noted when comparing the DA-IL-4-injected paws either to contralateral paws or to paws from rats treated with a control retrovirus. Evaluation of radiographs showed decreased joint destruction in the DA-IL-4-treated joints compared with the contralateral joints (P Ͻ 0.05) (see Figure 6 ).
Discussion
This is the first study to demonstrate clinical efficacy in an animal model of arthritis using direct intra-articular retroviral gene therapy. Gene therapy for arthritis has been the subject of intense investigation for several years. 19 The rationale for this approach lies in the need to deliver biologic agents over a prolonged period of time. Administration of therapeutic proteins to patients can be complicated by systemic side-effects or a short half-life, and gene therapy can potentially overcome these obstacles by providing continuous local production. A variety of delivery systems are currently available and can be tailored for a particular therapeutic gene. 20 For instance, adenoviruses are an extremely effective gene delivery system in a variety of settings by providing relatively short bursts of transgene expression. However, this vector has several limitations, including the production of viral proteins that elicit an acute inflammatory response. [21] [22] [23] Retroviral vectors, on the other hand, integrate into the host genome and are expressed for prolonged periods of time without production of viral proteins. 24, 25 Our efforts on gene therapy for arthritis have focused on the use of direct intra-articular injection of target genes using a variety of methods. Intra-articular therapy has some theoretic advantages over systemic administration with regard to safety and ease of administration. However, poor transfection efficiency has plagued previous attempts to use direct synovial injection of retroviral vectors in rodents. 20 We recently addressed several technical issues involving the use of retroviruses for treatment of arthritis. 18 These studies demonstrated that successful transgene expression using such constructs requires the presence of active synovitis, most likely because retroviruses only transduce dividing cells. In addition, successful gene transfer was only achieved when high titer retroviral preparations were used. In the rat adjuvant arthritis model, intra-articular injection of high titer (у10 9 CFU/ml) purified retrovirus established sustained levels of transgene expression. Synovial expression was maintained for at least 50 days, albeit at considerably lower levels than adenovirus. Of importance, there was little or no migration of retrovirus-transduced cells out of the injected joint to either the contralateral joint or other internal organs. When ␤-gal was used as a marker gene to assess gene transfer, its expression was typically 50-to 100-fold higher in the injected joint compared with the contralateral ankle throughout the 7 week experiment. Synovial expression was 10 3 -10 4 times higher than in internal organs such as spleen, liver and lung. Hence, the transgene remained localized to the site of administration.
Intra-articular retroviral gene delivery is, therefore, well-suited to cytokine therapy requiring long-lasting relatively low concentrations of the transgene product. To evaluate this method as a potential therapeutic modality, retroviral gene therapy was used to enhance synovial Th2 cytokine production in adjuvant arthritis. IL-4 was chosen as a therapeutic agent based on its antiinflammatory activities and its relative absence from the rheumatoid joint. Addition of exogenous IL-4 to cultures of RA synovial tissue cells or synovial tissue explants suppresses synthesis of pro-inflammatory cytokines such as IL-6, IL-1, TNF-␣, and GM-CSF as well as metalloproteinases. [26] [27] [28] These activities might be related to either suppression of Th1 function or a direct effect on synoviocytes and macrophages in RA. Furthermore, the potential usefulness of Th2 cytokines in RA is supported by the observation that T cell clones from rheumatoid joints tend to exhibit a Th1 phenotype.
29, 30 Significant amounts of IL-4 have not been detected in RA synovial fluid, and extremely sensitive nested RT-PCR techniques demonstrate essentially no IL-4 or IL-13 mRNA in RA synovial biopsies. 31 Finally, Th2 cytokine production is associated with the resolution of several arthritis models and delivery of exogenous IL-4 is effective in collagen-induced arthritis in mice.
Since human IL-4 lacks biological activity in the rat and is potentially immunogenic, high titer retrovirus preparations encoding the rat IL-4 gene were produced. Subsequent experiments demonstrated that this virus infects cultured FLS and increases production of immunoreactive IL-4. We then determined the ability of DA-IL-4 to increase IL-4 production after direct intra-articular gene transfer. Because the transgene product is indistinguishable from endogenous IL-4, we first characterized the cytokine profile during the course of adjuvant arthritis. These studies demonstrated that IL-4 increased progressively during the course of the disease in both control and DA-␤-gal-treated rats.
When arthritic rats were treated with DA-IL-4, an increase in immunoreactive IL-4 was detected in the injected, but not the contralateral, paw after 3 days. The difference between DA-IL-4-treated and control animals was modest but statistically significant. The amount of IL-4 detected in the injected joint continued to increase over the ensuing week. Surprisingly, IL-4 levels in the contralateral paw also increased in the DA-IL-4-treated animals during this period. Since the retrovirally transduced cells do not migrate to either internal organs or other joints in this model, alternative mechanisms likely explain this phenomenon. One hypothesis is that the presence of IL-4 in the injected joint provides an IL-4-rich environment that encourages Th2 differentiation in cells that traffic through the synovium. However, IL-4 protein levels were also increased in the serum of these animals and RT-PCR demonstrated higher levels of IL-4 gene expression only in the injected joint. This suggests that the treated ankle is the primary source of the cytokine detected at distant sites.
Concordant with increased expression of IL-4, intraarticular gene therapy also suppressed clinical arthritis in the treated joint. This was true whether the comparison was made with the contralateral joint or with animals treated with a control retroviral vector. The differences were unrelated to nonspecific effects of retrovirus injection or due to a host response to ␤-gal since this and previous studies showed that DA-␤-gal had no effect on cytokine production or paw swelling. 18 In addition to decreased swelling, bone destruction was decreased in the treated animals, possibly due to IL-4-mediated inhibition of metalloproteinase expression. Curiously, the contralateral paw did not improve despite the increase in IL-4 that occurred late in the disease. This contrasts with other gene therapy studies in which a 'contralateral effect' was described using NF-kB inhibitors or IL-1ra. 9, 10 In those reports, local intra-articular injection of adenoviral vectors led to improvement in both the treated and untreated paws. We have recently observed wide dispersal of transduced cells to other joints after intra-articular injection with adenoviral vectors (unpublished data), and this could contribute to distal effects in some models. The absence of a contralateral therapeutic effect in the current study could be due, in part, to the lack of trafficking of transduced cells when retroviral constructs are used. In addition, it is possible that the increase in IL-4 production observed in the contralateral paw is too late in the disease process to elicit a clinical response.
The applicability of these experiments to RA is, of course, still speculative. Adjuvant arthritis is an exuberant, extremely destructive model with a highly compressed time-course. Furthermore, the extent of synovial cell proliferation and the lineage of dividing cells might differ in RA compared with adjuvant arthritis. However, the experiments provide some proof of principle on the ability of subtle changes in the synovial cytokine milieu to alter the natural history of inflammatory arthritis. The notion that the joint can serve as a depot for the production of systemic cytokines has significant implications for immune regulation in arthritis. Furthermore, the utility of retroviruses as vectors for genes that require only low levels of expression was demonstrated.
In summary, this is the first study to demonstrate clinically successful direct intra-articular gene therapy in an arthritis model of arthritis using a retroviral vector. The data suggest that local gene therapy with a Th2 cytokine creates a synovial environment that can alter Th1/Th2 cytokines locally as well as in other sites. Since Th1/Th2 imbalance is a possible mechanism of disease perpetuation in rheumatoid arthritis, this approach might have therapeutic applicability.
Materials and methods
Vectors
The DA retroviral constructs are based on the Moloney mouse leukemia virus. Moloney gag and pol regions are preserved, along with amphotropic env proteins. The control retroviral vector DA-␤-gal, encoding the lacZ gene and neomycin resistance was constructed as previously described. 32 Full-length rat IL-4 cDNA was cloned by PCR from rat spleen RNA and its identity was confirmed by DNA sequencing. Packaged vectors were produced in 50 liter bulk culture by a derivative of the DA packaging cell line (D-17; ATCC, Rockville, MD, USA) and purified as previously described. The purification yielded retroviral particles suspended in an isotonic formulation buffer containing only NaCl and lactose, free of culture serum components. 33 Titer was determined in colony-forming units (CFU) by a colonyformation assay using HT 1080 (human fibrosarcoma; ATCC) selected in medium containing G418 (Geneticin; Gibco/Life Technologies, Grand Island, NY, USA). All vector lots used in these studies were free of detectable replication-competent retrovirus, as determined by S+/L− assay. 34 Reagents Chemicals were obtained from Sigma Chemical (St Louis, MO, USA) unless otherwise indicated.
Isolation and culture of fibroblast-like synoviocytes (FLS) FLS used for in vitro synoviocyte infection studies were obtained from patients undergoing total joint replacement who met the 1987 revised American College of Rheumatology criteria for RA. 35 Harvested synovium was enzymatically dispersed as previously described. 36 FLS were used from passage 3 to 8 during which time they were a homogeneous population of cells (Ͻ1% CD11b positive, Ͻ1% phagocytic, and Ͻ1% FcR II and FcR III receptor positive).
In vitro gene transfer
For in vitro cell transduction, RA FLS were cultured in six-well plastic plates (Costar Corporation, Cambridge, MA, USA) at 33 000 cells per well in DMEM/10% FCS in a humidified 5% CO 2 atmosphere. After 48 h, the cells were transduced with 2 ml of DMEM/10% FCS containing 0-10 6 CFU of DA-IL-4 in the presence of polybrene at 8 g/ml and incubated at 37°C. Cell supernatants were subsequently harvested at various time-points and assayed for IL-4.
Adjuvant arthritis model
Male Lewis rats (125-150 g) were immunized at the base of the tail on day 0 with 0.1 ml of complete Freund's adjuvant comprised of mineral oil and heat killed mycobacteria tuberculosis. 37 The course of the arthritis was monitored by determining paw volume with a water displacement plethysmometor. Obvious paw swelling was observed by days 10-12. Previous studies demonstrated that optimal transduction using retroviral vectors occurred from days 10 to 20. Therefore, animals were anesthetized on day 12 and administered an intra-articular injection into the right ankle of retrovirus (see below). Rats were killed by CO 2 narcosis at various time-points to determine transgene expression. All animals were handled in accordance with UCSD Animal Subjects Committee and USDA guidelines. For radiographic analysis, the following semi-quantitative scale was used: demineralization (0-2+), erosion (0-2+), heterotopic bone formation (0-1+), and calcaneal erosion (0-1+).
In vivo gene transfer On day 12, animals were anesthetized with methoxyfluorane and treated with DA-␤-gal or DA-IL-4. The skin was prepped with ethyl alcohol and the right ankle joint was held in 15-20 degrees of plantar flexion. A 31-g needle mounted on a 100 l glass syringe was inserted anterolaterally at the ankle joint line about 1-2 mm distal to the lateral malleolus. Fifty microliters of DA-␤-gal or DA-IL-4 retroviral vector (5 × 10 7 CFU) were injected intra-articularly. IL-4 or IFN-␥ were determined by ELISA.
Detection of cytokines by ELISA Ankle joints were trimmed of skin and cut at the Achilles tendon and the mid-foot and weighed. The harvested ankle joints were then cut into small pieces and homogenized in lysis solution (100 mm potassium phosphate pH 7.8, 0.2% Triton X-100, 1 mm DTT) using a tissue homogenizer. The volume of lysis solution was adjusted to a final concentration of 0.5 g of tissue per ml. Homogenized tissue solutions were centrifuged for 10 minutes at 12 000 g at 4°C to remove insoluble debris. Rat IL-4 levels were measured in the lysates by antibody capture ELISA. A microtiter plate was coated with 100 l per well of affinity purified goat anti-rat IL-4 antibody (R&D Systems, Minneapolis, MN, USA), 2 g/ml in PBS with 0.1% azide, and incubated overnight at 4°C in a humidified chamber. Plates were then blocked in 1× PBS, 2% (w/v) teleost gelatin and 0.1% (w/v) azide. Plates were washed extensively in 1× PBS, 0.05% (v/v) Tween-20. Standards (R&D Systems) or samples were then added to each well and incubated for 3 h at 37°C, 100% humidity. After washing, purified monoclonal mouse anti-rat-IL-4 (1 g/ml) (Pharmingen, San Diego, CA, USA) was added and incubated for 1 h at room temperature. Peroxidase-conjugated goat anti-mouse IgG1 (1:1000) (Southern Biotechnologies, Birmingham, AL, USA) was then added and incubated for 1 h at 37°C. After a final wash, TMB substrate was added (Bio-Rad, Hercules, CA, USA). The reaction was stopped by the addition of 1 n H 2 SO 4 . Plates were read at OD of 450 nm. Rat interferon-gamma (rat anti-IFN-␥) was detected by the Cytoscreen Immunoassay kit (BioSource International, Camarillo, CA, USA) as described by the manufacturer.
RT-PCR detection of IL-4 mRNA in rat ankles The skin was removed from excised ankle joints and the joint samples were snap-frozen and pulverized. Total RNA was obtained from paws with RNA STAT-60 (Tel Test, Friendswood, TX, USA), according to the manufacturer's instructions. RNA was pooled, quantified spectrophotometrically and the concentrations were normalized. Reverse transcription was performed using the Prostar first strand RT-PCR kit (Stratagene, La Jolla, CA, USA) for first-strand cDNA synthesis. PCR amplification was performed using the CORE PCR kit (Qiagen, Chatsworth, CA, USA). RNA quantity and quality was determined by amplification of rat glyceraldehyde 3-phosphate dehydrogenase (G3PDH) using commercial primers (Clontech, Palo Alto, CA, USA). IL-4 mRNA was amplified using primers specific to rat IL-4 (Retrogen, San Diego, CA, USA) and derived from the Genbank sequence (accession No. 16058). The region amplified was selected such that both native and transgene-derived IL-4 mRNA would be amplified. Upstream and downstream IL-4 primer sequences (5Ј to 3Ј) were as follows: TCT CAC GTC ACT GAC TGT AGA G and CTT TCA GTG TTG TGA GCG TGG. PCR products were separated by agarose gel electrophoresis and visualized by ethidium bromide staining.
Statistics
Statistical analysis was performed by paired or unpaired Student's t test. Data are presented as mean ± s.e.m.
